Arlington、VAにおける乳がんの臨床試験
Arlingtonとその周辺地域（約30マイル以内）の拠点で、乳がんに関する47件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Virginia Cancer Specialists, PC, Fairfax · 11マイル先
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology - Virginia, Fairfax · 11マイル先
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
被験者募集中第1/2相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Virginia Cancer Specialists, PC, Fairfax · 11マイル先
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
被験者募集中第2相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
Study of AVZO-021 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Fairfax · 11マイル先
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 11マイル先
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Fairfax · 11マイル先
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Inova, Fairfax · 11マイル先
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
被験者募集中第1相
- Next Virginia, Fairfax · 11マイル先
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- NEXT Oncology, Fairfax · 11マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Virginia Cancer Specialists, Fairfax · 11マイル先
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11マイル先
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Oncology, Fairfax · 11マイル先
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Next Oncology, Fairfax · 11マイル先
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
被験者募集中第1/2相
- Virginia Cancer Specialists-Fairfax, Fairfax · 11マイル先
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5マイル先
- Kaiser Permanente-Burke Medical Center, Burke · 11マイル先
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- Inova Schar Cancer Institute, Falls Church · 4マイル先
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- Inova Fair Oaks Hospital, Fairfax · 11マイル先
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Virginia Cancer Specialists, Fairfax · 11マイル先
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Inova Fairfax Hospital, Falls Church · 4マイル先
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5マイル先
- Inova Schar Cancer Institute, Fairfax · 11マイル先
- 他1件
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Virginia Cancer Specialists, Fairfax · 11マイル先
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
被験者募集中第1相
- NEXT Virginia, Fairfax · 11マイル先
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- USO-Virginia Cancer Specialists, PC, Fairfax · 11マイル先
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
被験者募集中第3相
- INOVA Schar Cancer, Fairfax · 11マイル先
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- NEXT Oncology Virginia, Fairfax · 11マイル先
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- NEXT, Fairfax · 11マイル先
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
被験者募集中第1/2相
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 11マイル先
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Virginia Cancer Specialists, PC, Reston · 14マイル先
- Virginia Cancer Specialists, Manassas · 22マイル先
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
被験者募集中第1相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- NEXT Oncology Virginia, Fairfax · 11マイル先
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- NEXT Virginia, Fairfax · 11マイル先
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Virginia Cancer Specialists, Fairfax · 11マイル先
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
被験者募集中第1/2相
- NEXT, Virginia, Fairfax · 11マイル先
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
被験者募集中第1相
- Inova Schar Cancer Center, Fairfax · 11マイル先
- NEXT Virginia, Fairfax · 11マイル先
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
被験者募集中第1相
- Biotheryx Investigative Site, Fairfax · 11マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Arlingtonにおける他の研究
- 非小細胞肺癌104件の研究
- 転移性癌53件の研究
- 大腸癌52件の研究
- がん（全種類）48件の研究
- 卵巣がん46件の研究
- 肺がん41件の研究
- 子宮内膜がん39件の研究
- 膵臓がん33件の研究
- 頭頸部扁平上皮癌26件の研究
- 小細胞肺がん23件の研究
- 胃癌20件の研究
- トリプルネガティブ乳がん20件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。